A Phase 2 interventional study of Nilotinib followed by treatment-free in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 113 sites in 19 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 10th largest by enrollment, is one of 11 that started in 2013, is one of 25 in phase 2, and was the 42nd registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 17th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2013, is one of 19 in phase 2, and was the 52nd registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
The Primary objective of this study was to determine the percentage of patients who were in Major Molecular Response (MMR) at 48 weeks after starting the Treatment-Free Remission (TFR) phase (patients who required re-initiation of treatment were considered as non-responders).
Nilotinib treatment consolidation phase (NTCS): Patients who satisfied all inclusion/exclusion criteria were enrolled in the consolidation phase and continued to receive nilotinib for 52 weeks. All patients were treated with the planned nilotinib dose 300 mg BID (or at a reduced dose level of 400 mg QD if required from the perspective of toxicity). In order for patients to be eligible for the TFR phase, they had to fulfill the protocol specific definition of durable MRD. The four last quarterly performed PCR assessments must have fulfilled the following criteria:
Nilotinib Treatment-Free Remission (TFR) phase: Patients who were eligible to enter in the TFR phase after completing the 52 weeks consolidation phase, stopped taking nilotinib on the first day of the TFR phase. Duration of this phase was up to 10 years after the last patient enters in the TFR phase. BCR-ABL levels were monitored every four weeks during the first 48 weeks, every six weeks for the following 48 weeks and every 12 weeks during the last period.
Nilotinib treatment re-initiation (NTRI) phase: If a patient had a loss of MMR (BCR-ABL >0.1% IS) in the TFR phase, the patient restarted nilotinib treatment. Patients were on nilotinib treatment for up to 10 years after the last patient entered the nilotinib TFR phase. Patients who required re-initiation of nilotinib treatment were monitored for the BCR-ABL level every four weeks for the first 24 weeks and then every 12 weeks thereafter in patients who regained MMR. The frequency of BCR-ABL monitoring in patients not regaining MMR within the first 24 weeks after re-initiation of treatment was at least every 12 weeks or more frequently as clinically indicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate end organ function as defined by:
Patients must have the following electrolyte values within normal limits or corrected to be within normal limits with supplements prior to first dose of study medication:
Patients must have normal marrow function as defined:
Documented chronic phase CML must meet all the criteria defined by:
Exclusion Criteria:
Impaired cardiac function including any one of the following:
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during the study and for 14 days after the final dose of nilotinib. Highly effective contraception is defined as either:
Use of a combination of any two of the following:
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to enrolling. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
If a study patient becomes pregnant or suspects being pregnant during the study or within 30 days after the final dose of nilotinib, the Study Doctor needs to be informed immediately and ongoing study treatment with nilotinib has to be stopped immediately.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 entered the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase entered the Treatment-Free Remission (TFR) phase where no treatment was given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
Drug: Nilotinib followed by treatment-free
Drug page: Nilotinib
Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
Also known as: AMN107
Percentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase
The primary endpoint was the percentage of participants in major molecular response (MMR) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment were considered as non-responders.
Time frame: 48 weeks in TFR
Percentage of Participants in MR4.5 (BCR-ABL ≤ 0.0032% IS) at 48 Weeks After Start of TFR Phase
The outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS), representing a deep molecular response.
Time frame: 48 weeks in TFR
Percentage of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
This outcome measure was the percentage of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment at any time prior to the respective assessment were considered non-responders.
Time frame: Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Percentage of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
This secondary outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment at any time prior to the respective assessment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).
Time frame: Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Number of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
This outcome measure was the number of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MMR data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point.
Time frame: Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Number of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
This outcome measure was the number of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MR4.5 data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).
Time frame: Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Percentage of Participants Who Achieved Major Molecular Response (MMR) Within 12 Weeks of Reinitiation of Nilotinib Treatment
Percentage of patients who achieved MMR within 12 weeks of re-initiation of treatment with nilotinib defined as the number of patients who were in MMR at least at 1 assessment within 12 weeks after re-start of nilotinib treatment divided by the number of patients who were re-initiated for at least 12 weeks.
Time frame: 12 weeks after reinitiation of nilotinib treatment
Percentage of Participants With Stable Major Molecular Response (MMR) at Multiple Time Points After First Achievement of MMR During Nilotinib Re-Initiation
The percentage of patients who were in stable MMR after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MMR any time during the NTRI phase and having the same response at those timepoints after the first achievement of MMR, irrespective of whether there was loss of MMR in between, by the number of patients who achieved MMR at any time during the NTRI phase.
Time frame: Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MMR during the nilotinib re-initiation phase
Percentage of Participants With Stable Molecular Response 4.5 (MR4.5) at Multiple Time Points After First Achievement During Nilotinib Re-Initiation
The proportion of patients who were in stable MR4.5 after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MR4.5 any time during the NTRI phase and having the same response at those timepoints after the first achievement of MR4.5, irrespective of whether there was loss of MR4.5 in between, by the number of patients who achieved MR4.5 at any time during the NTRI phase.
Time frame: Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MR4.5 during the nilotinib re-initiation phase
BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)
The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.
Time frame: Baseline; every 4 weeks up to Week 24; and every 12 weeks thereafter, up to Week 528
Duration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR
This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of MMR. Participants who did not regain MMR after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment.
Time frame: Every 4 weeks up to Week 24, and every 12 weeks thereafter, up to Week 528
Duration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR
This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of molecular response 4.5 (MR4.5). Participants who did not regain MR4.5 after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment. MR4.5 corresponds to a BCR-ABN transcript level ≤0.0032% on the International Scale (IS).
Time frame: From start of Nilotinib treatment re-initiation up to Week 528
Treatment-Free Survival (TFS) After Start of the Treatment-Free Remission (TFR) Phase
Treatment-free survival (TFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of loss of major molecular response (MMR), reinitiation of treatment for any reason, progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (polymerase chain reaction, cytogenetic, hematologic, or extramedullary assessment).
Time frame: From start of the treatment-free remission (TFR) phase up to Week 528
Progression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) Phase
Progression-free survival (PFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of disease progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (cytogenetic, hematologic, or extramedullary assessment) or last contact for participants in follow-up.
Time frame: From start of the treatment-free remission (TFR) phase up to Week 528
Overall Survival (OS) After Start of the Treatment-Free Remission (TFR) Phase
Overall survival (OS) was defined as the time from the start of the treatment-free remission (TFR) phase to death due to any cause. Participants who were alive on or before the data cut-off date were censored at the date of their last assessment or last known alive date for participants in follow-up.
Time frame: From start of the treatment-free remission (TFR) phase up to Week 528
Percentage of Participants With Treatment-emergent Adverse Events During the Entire Study
This outcome measure summarized the overall occurrence of adverse events related to nilotinib during the study. A study drug-related adverse event was defined as any adverse event assessed by the investigator as related to nilotinib and reported during the nilotinib treatment consolidation (NTCS) phase, the treatment-free remission (TFR) phase, or the nilotinib treatment re-initiation (NTRI) phase.
Time frame: From first dose of nilotinib through up to approximately 11 years of study participation, including the NTCS, TFR, and NTRI phases
Number of Participants With BCR-ABL1 Mutations Associated With Resistance to Nilotinib After Loss of Major Molecular Response
This outcome measure was the number of participants who developed BCR-ABL1 mutations associated with resistance to nilotinib following loss of major molecular response (MMR) after suspension of nilotinib treatment. Mutations assessed included, but were not limited to, T315I, E255K, Y253H, F359V, F359C, and F359I. The endpoint was calculated as the number of participants with at least one detected BCR-ABL1 mutation divided by the number of participants who experienced loss of MMR after nilotinib suspension.
Time frame: From loss of major molecular response after nilotinib suspension through up to 528 weeks of study participation
Recruitment for the study comprised a total of 215 participants, who were enrolled at 132 clinical sites distributed across 19 different countries..
| Milestone | Nilotinib Treatment and Treatment-Free Remission Cohort |
|---|---|
| Started | 215 |
| Completed | 203 |
| Not completed | 12 |
| Withdrew: Adverse event | 5 |
| Withdrew: Physician decision | 2 |
| Withdrew: Patient/guardian decision | 3 |
| Withdrew: Death | 2 |
| Milestone | Nilotinib Treatment and Treatment-Free Remission Cohort |
|---|---|
| Started | 190 |
| Completed | 65 |
| Not completed | 125 |
| Withdrew: Patient/guardian decision | 18 |
| Withdrew: Lack of efficacy | 98 |
| Withdrew: Death | 2 |
| Withdrew: Physician decision | 4 |
| Withdrew: Lost to follow-up | 3 |
The primary endpoint was the percentage of participants in major molecular response (MMR) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment were considered as non-responders.
| percentage of participants | TFR Phase |
|---|---|
| Percentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase | 51.6 (44.2 to 58.9) |
The outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS), representing a deep molecular response.
| percentage of participants | TFR Phase |
|---|---|
| Percentage of Participants in MR4.5 (BCR-ABL ≤ 0.0032% IS) at 48 Weeks After Start of TFR Phase | 47.4 (40.1 to 54.7) |
This outcome measure was the percentage of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment at any time prior to the respective assessment were considered non-responders.
| percentage of participants | TFR Phase |
|---|---|
| Week 96 response | 48.9 (41.6 to 56.3) |
| Week 144 response | 46.8 (39.6 to 54.2) |
| Week 192 response | 44.7 (37.5 to 52.1) |
| Week 264 response | 41.6 (34.5 to 48.9) |
| Week 312 (Year 6) response | 38.4 (31.5 to 45.7) |
| Week 360 (Year 7) response | 37.4 (30.5 to 44.7) |
| Week 408 (year 8) response | 35.3 (28.5 to 42.5) |
| Week 468 (year 9) response | 34.2 (27.5 to 41.4) |
| Week 528 (year 10) response | 26.8 (20.7 to 33.7) |
This secondary outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment at any time prior to the respective assessment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).
| percentage of participants | TFR Phase |
|---|---|
| Week 96 response | 46.3 (39.1 to 53.7) |
| Week 144 response | 45.8 (38.6 to 53.2) |
| Week 192 response | 43.2 (36.0 to 50.5) |
| Week 264 response | 40.0 (33.0 to 47.3) |
| Week 312 (Year 6) response | 37.9 (31.0 to 45.2) |
| Week 360 (Year 7) response | 36.3 (29.5 to 43.6) |
| Week 408 (year 8) response | 35.3 (28.5 to 42.5) |
| Week 468 (year 9) response | 33.7 (27.0 to 40.9) |
| Week 528 (year 10) response | 25.3 (19.3 to 32.1) |
This outcome measure was the number of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MMR data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point.
| Participants | TFR Phase |
|---|---|
| Week 48 response | 98 |
| Week 96 response | 93 |
| Week 144 response | 89 |
| Week 192 response | 85 |
| Week 264 response | 79 |
| Week 312 (Year 6) response | 73 |
| Week 360 (Year 7) response | 71 |
| Week 408 (year 8) response | 67 |
| Week 468 (year 9) response | 65 |
| Week 528 (year 10) response | 51 |
This outcome measure was the number of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MR4.5 data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).
| Participants | TFR Phase |
|---|---|
| Week 48 response | 90 |
| Week 96 response | 88 |
| Week 144 response | 87 |
| Week 192 response | 82 |
| Week 264 response | 76 |
| Week 312 (Year 6) response | 72 |
| Week 360 (Year 7) response | 69 |
| Week 408 (year 8) response | 67 |
| Week 468 (year 9) response | 64 |
| Week 528 (year 10) response | 48 |
Percentage of patients who achieved MMR within 12 weeks of re-initiation of treatment with nilotinib defined as the number of patients who were in MMR at least at 1 assessment within 12 weeks after re-start of nilotinib treatment divided by the number of patients who were re-initiated for at least 12 weeks.
| percentage of participants | NTRI Phase |
|---|---|
| Percentage of Participants Who Achieved Major Molecular Response (MMR) Within 12 Weeks of Reinitiation of Nilotinib Treatment | 95.4 (88.6 to 98.7) |
The percentage of patients who were in stable MMR after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MMR any time during the NTRI phase and having the same response at those timepoints after the first achievement of MMR, irrespective of whether there was loss of MMR in between, by the number of patients who achieved MMR at any time during the NTRI phase.
| percentage of participants | NTRI Phase |
|---|---|
| Stable MMR for 48 weeks | 84.3 (75.0 to 91.1) |
| Stable MMR for 96 weeks | 78.7 (68.7 to 86.6) |
| Stable MMR for 144 weeks | 68.5 (57.8 to 78.0) |
| Stable MMR for 192 weeks | 60.7 (49.7 to 70.9) |
| Stable MMR for 240 weeks | 48.3 (37.6 to 59.2) |
| Stable MMR for 288 weeks | 42.7 (32.3 to 53.6) |
| Stable MMR for 336 weeks | 38.2 (28.1 to 49.1) |
| Stable MMR for 384 weeks | 34.8 (25.0 to 45.7) |
| Stable MMR for 432 weeks | 30.3 (21.0 to 41.0) |
The proportion of patients who were in stable MR4.5 after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MR4.5 any time during the NTRI phase and having the same response at those timepoints after the first achievement of MR4.5, irrespective of whether there was loss of MR4.5 in between, by the number of patients who achieved MR4.5 at any time during the NTRI phase.
| percentage of participants | NTRI Phase |
|---|---|
| Stable MR4.5 for 48 weeks | 86.9 (77.8 to 93.3) |
| Stable MR4.5 for 96 weeks | 76.2 (65.7 to 84.8) |
| Stable MR4.5 for 144 weeks | 71.4 (60.5 to 80.8) |
| Stable MR4.5 for 192 weeks | 63.1 (51.9 to 73.4) |
| Stable MR4.5 for 240 weeks | 48.8 (37.7 to 60.0) |
| Stable MR4.5 for 288 weeks | 42.9 (32.1 to 54.1) |
| Stable MR4.5 for 336 weeks | 39.3 (28.8 to 50.5) |
| Stable MR4.5 for 384 weeks | 35.7 (25.6 to 46.9) |
| Stable MR4.5 for 432 weeks | 31.0 (21.3 to 42.0) |
The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.
| Percent | NTRI Phase |
|---|---|
| Baseline | 0.22697 ± 0.194306 |
| Week 4 | 0.43848 ± 1.302378 |
| Week 8 | 0.14038 ± 0.527741 |
| Week 12 | 0.03205 ± 0.172524 |
| Week 16 | 0.01044 ± 0.055724 |
| Week 20 | 0.00476 ± 0.027446 |
| Week 24 | 0.00291 ± 0.011041 |
| Week 36 | 0.00209 ± 0.010182 |
| Week 48 | 0.00149 ± 0.007022 |
| Week 60 | 0.00120 ± 0.006373 |
| Week 72 | 0.00098 ± 0.003366 |
| Week 84 | 0.00120 ± 0.006416 |
| Week 96 | 0.00169 ± 0.010148 |
| Week 108 | 0.00492 ± 0.032543 |
| Week 120 | 0.00073 ± 0.002945 |
| Week 132 | 0.00055 ± 0.002217 |
| Week 144 | 0.00068 ± 0.002429 |
| Week 156 | 0.00074 ± 0.003559 |
| Week 168 | 0.00071 ± 0.003267 |
| Week 180 | 0.00047 ± 0.001156 |
| Week 192 | 0.00262 ± 0.016285 |
| Week 204 | 0.01753 ± 0.126293 |
| Week 216 | 0.00683 ± 0.048460 |
| Week 228 | 0.00427 ± 0.029012 |
| Week 240 | 0.00315 ± 0.016585 |
| Week 252 | 0.00660 ± 0.029570 |
| Week 264 | 0.01436 ± 0.061134 |
| Week 276 | 0.01784 ± 0.081702 |
| Week 288 | 0.01616 ± 0.098699 |
| Week 300 | 0.01865 ± 0.113939 |
| Week 312 | 0.02516 ± 0.124114 |
| Week 324 | 0.01939 ± 0.113715 |
| Week 336 | 0.01348 ± 0.078374 |
| Week 348 | 0.00801 ± 0.045810 |
| Week 360 | 0.01015 ± 0.057496 |
| Week 372 | 0.00509 ± 0.028312 |
| Week 384 | 0.00206 ± 0.010247 |
| Week 396 | 0.00137 ± 0.006892 |
| Week 408 | 0.00158 ± 0.007350 |
| Week 420 | 0.00171 ± 0.008446 |
| Week 432 | 0.00102 ± 0.004642 |
| Week 444 | 0.00057 ± 0.002430 |
| Week 456 | 0.00084 ± 0.002877 |
| Week 468 | 0.00083 ± 0.003204 |
| Week 480 | 0.03371 ± 0.156501 |
| Week 492 | 0.00062 ± 0.002046 |
| Week 504 | 0.00044 ± 0.001246 |
| Week 516 | 0.00073 ± 0.001920 |
| Week 528 | 0.00000 |
This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of MMR. Participants who did not regain MMR after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment.
| Weeks | NTRI Phase |
|---|---|
| Duration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR | 7.0 (5.0 to 8.0) |
This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of molecular response 4.5 (MR4.5). Participants who did not regain MR4.5 after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment. MR4.5 corresponds to a BCR-ABN transcript level ≤0.0032% on the International Scale (IS).
| Weeks | NTRI Phase |
|---|---|
| Duration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR | 12.9 (12.1 to 15.1) |
Treatment-free survival (TFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of loss of major molecular response (MMR), reinitiation of treatment for any reason, progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (polymerase chain reaction, cytogenetic, hematologic, or extramedullary assessment).
| Weeks | TFR Phase |
|---|---|
| Treatment-Free Survival (TFS) After Start of the Treatment-Free Remission (TFR) Phase | 120.1 (36.9 to NA) |
Progression-free survival (PFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of disease progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (cytogenetic, hematologic, or extramedullary assessment) or last contact for participants in follow-up.
| Weeks | TFR Phase |
|---|---|
| Progression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) Phase | NA (NA to NA) |
Overall survival (OS) was defined as the time from the start of the treatment-free remission (TFR) phase to death due to any cause. Participants who were alive on or before the data cut-off date were censored at the date of their last assessment or last known alive date for participants in follow-up.
| Weeks | TFR Phase |
|---|---|
| Overall Survival (OS) After Start of the Treatment-Free Remission (TFR) Phase | NA (NA to NA) |
This outcome measure summarized the overall occurrence of adverse events related to nilotinib during the study. A study drug-related adverse event was defined as any adverse event assessed by the investigator as related to nilotinib and reported during the nilotinib treatment consolidation (NTCS) phase, the treatment-free remission (TFR) phase, or the nilotinib treatment re-initiation (NTRI) phase.
| Participants | NTCS Phase | TFR Phase | NTRI Phase |
|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events During the Entire Study | 83 | 40 | 70 |
This outcome measure was the number of participants who developed BCR-ABL1 mutations associated with resistance to nilotinib following loss of major molecular response (MMR) after suspension of nilotinib treatment. Mutations assessed included, but were not limited to, T315I, E255K, Y253H, F359V, F359C, and F359I. The endpoint was calculated as the number of participants with at least one detected BCR-ABL1 mutation divided by the number of participants who experienced loss of MMR after nilotinib suspension.
| Participants | TFR Phase |
|---|---|
| Number of Participants With BCR-ABL1 Mutations Associated With Resistance to Nilotinib After Loss of Major Molecular Response | 1 |
Collected over From first dose of nilotinib through up to approximately 11 years of study participation, including the NTCS phase (up to 52 weeks), TFR phase (up to 528 weeks), and NTRI phases (up to 500 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NTCS | 2/215 (0.9%) | 20/215 (9.3%) | 159/215 (74%) |
| TFR Phase | 2/190 (1.1%) | 34/190 (17.9%) | 136/190 (71.6%) |
| NTRI | 5/91 (5.5%) | 40/91 (44%) | 86/91 (94.5%) |
| NTCT | 0/13 (0%) | 1/13 (7.7%) | 11/13 (84.6%) |
| TFR-2 | 0/10 (0%) | 1/10 (10%) | 7/10 (70%) |
| NTRI-2 | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| NTCT-P | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| All Patients | 9/215 (4.2%) | 84/215 (39.1%) | 205/215 (95.3%) |
| Event | NTCS | TFR Phase | NTRI | NTCT | TFR-2 | NTRI-2 | NTCT-P | All Patients |
|---|---|---|---|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/215 | 1/190 | 1/91 | 0/13 | 0/10 | 1/5 | 0/3 | 3/215 |
| Cardiac failureCardiac disorders | 0/215 | 1/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 2/215 |
| Coronary artery diseaseCardiac disorders | 0/215 | 0/190 | 3/91 | 0/13 | 0/10 | 1/5 | 0/3 | 4/215 |
| Coronary artery occlusionCardiac disorders | 0/215 | 0/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 1/215 |
| Abdominal herniaGastrointestinal disorders | 0/215 | 0/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 1/215 |
| SepsisInfections and infestations | 0/215 | 0/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 1/215 |
| Urinary tract infectionInfections and infestations | 0/215 | 0/190 | 1/91 | 0/13 | 0/10 | 1/5 | 0/3 | 2/215 |
| SeromaInjury, poisoning and procedural complications | 0/215 | 0/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 1/215 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/215 | 3/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 4/215 |
| Cerebral infarctionNervous system disorders | 0/215 | 0/190 | 0/91 | 0/13 | 0/10 | 1/5 | 0/3 | 1/215 |
| Event | NTCS | TFR Phase | NTRI | NTCT | TFR-2 | NTRI-2 | NTCT-P | All Patients |
|---|---|---|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 8/215 | 12/190 | 6/91 | 1/13 | 1/10 | 3/5 | 0/3 | 30/215 |
| NasopharyngitisInfections and infestations | 22/215 | 32/190 | 19/91 | 0/13 | 0/10 | 2/5 | 0/3 | 58/215 |
| SinusitisInfections and infestations | 3/215 | 9/190 | 4/91 | 0/13 | 1/10 | 2/5 | 0/3 | 17/215 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/215 | 44/190 | 14/91 | 1/13 | 3/10 | 2/5 | 0/3 | 73/215 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 7/215 | 18/190 | 3/91 | 0/13 | 0/10 | 2/5 | 0/3 | 30/215 |
| HeadacheNervous system disorders | 10/215 | 23/190 | 11/91 | 1/13 | 1/10 | 2/5 | 0/3 | 42/215 |
| Oral disorderGastrointestinal disorders | 0/215 | 0/190 | 0/91 | 0/13 | 0/10 | 0/5 | 1/3 | 1/215 |
| COVID-19Infections and infestations | 0/215 | 21/190 | 7/91 | 0/13 | 1/10 | 1/5 | 1/3 | 31/215 |
| FolliculitisInfections and infestations | 4/215 | 0/190 | 1/91 | 0/13 | 1/10 | 0/5 | 1/3 | 7/215 |
| FuruncleInfections and infestations | 0/215 | 1/190 | 0/91 | 0/13 | 0/10 | 0/5 | 1/3 | 2/215 |
| Age, Continuous(years) | NTCS Phase |
|---|---|
| Median | 54.0 (21 to 86) |
| Sex: Female, Male(Participants) | NTCS Phase |
|---|---|
| Female | 102 |
| Male | 113 |
| Race/Ethnicity, Customized(participants) | NTCS Phase |
|---|---|
| Caucasian | 189 |
| Asian | 20 |
| Unknown | 3 |
| Native American | 1 |
| Other | 2 |
Showing the first 100 of 113 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2013 to primary completion in May 2016, 38 months.
Results were first posted in Jan 2021, 4 years 7 months after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 38 months is below that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →